Dills D G
University of Colorado Department of Medicine, University of Colorado Health Sciences Center, F-732 Anschutz Center for Advanced Medicine, 1635 N. Ursula Street, Aurora, CO 80010, USA.
Curr Diab Rep. 2001 Oct;1(2):112-8. doi: 10.1007/s11892-001-0022-x.
Tight control of the blood glucose level decreases the frequency of complications of both type 1 and type 2 diabetes mellitus. Until recently, the available short, intermediate, and long-acting forms of insulin could not readily be used to achieve tight glycemic control without introducing an unacceptably high risk of hypoglycemia or demanding an impracticably rigid lifestyle. With the introduction of faster-acting insulin analogues, lispro and aspart, and a peakless long-acting insulin analogue, glargine, the goal of safe and effective tight glycemic control may now be within reach for many patients. The use of these new insulins allows the clinician and patient an expanded range of options for achieving good control of fasting and postprandial blood glucose levels.
严格控制血糖水平可降低1型和2型糖尿病并发症的发生频率。直到最近，现有的短效、中效和长效胰岛素制剂，若不带来难以接受的高低血糖风险或要求不切实际的严格生活方式，就无法轻易用于实现严格的血糖控制。随着速效胰岛素类似物赖脯胰岛素和门冬胰岛素，以及无峰值长效胰岛素类似物甘精胰岛素的推出，安全有效的严格血糖控制目标现在可能对许多患者来说触手可及。使用这些新型胰岛素使临床医生和患者在实现空腹和餐后血糖水平良好控制方面有了更多的选择。
